Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. lifted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 1.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,841,969 shares of the company's stock after buying an additional 218,025 shares during the quarter. Vanguard Group Inc. owned about 4.79% of Amneal Pharmaceuticals worth $117,548,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the stock. Franklin Resources Inc. grew its position in shares of Amneal Pharmaceuticals by 4.9% during the third quarter. Franklin Resources Inc. now owns 89,887 shares of the company's stock worth $778,000 after acquiring an additional 4,178 shares during the last quarter. Arizona State Retirement System boosted its stake in Amneal Pharmaceuticals by 13.6% during the 4th quarter. Arizona State Retirement System now owns 40,401 shares of the company's stock worth $320,000 after purchasing an additional 4,851 shares during the period. Globeflex Capital L P grew its position in Amneal Pharmaceuticals by 3.8% during the 4th quarter. Globeflex Capital L P now owns 144,439 shares of the company's stock worth $1,144,000 after purchasing an additional 5,245 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in Amneal Pharmaceuticals by 13.6% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 46,240 shares of the company's stock worth $366,000 after purchasing an additional 5,523 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in Amneal Pharmaceuticals by 1.2% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 555,655 shares of the company's stock valued at $4,401,000 after purchasing an additional 6,680 shares during the period. 31.82% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Trading Up 0.1 %

Shares of AMRX traded up $0.01 during mid-day trading on Friday, hitting $6.98. The company's stock had a trading volume of 1,807,041 shares, compared to its average volume of 1,398,679. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.18 and a 1-year high of $9.48. The firm has a market capitalization of $2.16 billion, a P/E ratio of -10.26 and a beta of 1.06. The firm has a 50-day simple moving average of $8.17 and a 200 day simple moving average of $8.28.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. The business had revenue of $730.52 million during the quarter, compared to analyst estimates of $708.21 million. During the same period last year, the business posted $0.14 EPS. As a group, sell-side analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on AMRX shares. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $9.00 to $12.00 in a research note on Monday, February 24th. Barclays increased their price objective on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research report on Monday, March 3rd. Finally, StockNews.com lowered Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, December 19th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Amneal Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $10.80.

Insider Buying and Selling

In related news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction on Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the completion of the transaction, the insider now directly owns 48,578,209 shares of the company's stock, valued at approximately $405,628,045.15. The trade was a 9.33 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Gautam Patel sold 80,000 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.90, for a total value of $712,000.00. Following the completion of the sale, the director now directly owns 1,808,886 shares in the company, valued at $16,099,085.40. This trade represents a 4.24 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,160,000 shares of company stock valued at $43,113,200. Corporate insiders own 26.56% of the company's stock.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.